TY - JOUR AU - Alomari, A. I. AU - Spencer, S. A. AU - Arnold, R. W. PY - 2014 DA - 2014// TI - Fibro-adipose vascular anomaly: clinical-radiologic-pathologic features of a newly delineated disorder of the extremity JO - J Pediatr Orthop VL - 34 UR - https://doi.org/10.1097/BPO.0b013e3182a1f0b8 DO - 10.1097/BPO.0b013e3182a1f0b8 ID - Alomari2014 ER - TY - JOUR AU - Shaikh, R. AU - Alomari, A. I. AU - Kerr, C. L. AU - Miller, P. AU - Spencer, S. A. PY - 2016 DA - 2016// TI - Cryoablation in fibro-adipose vascular anomaly (FAVA): a minimally invasive treatment option JO - Pediatr Radiol VL - 46 UR - https://doi.org/10.1007/s00247-016-3576-0 DO - 10.1007/s00247-016-3576-0 ID - Shaikh2016 ER - TY - JOUR AU - Erickson, J. AU - McAuliffe, W. AU - Blennerhassett, L. AU - Halbert, A. PY - 2017 DA - 2017// TI - Fibroadipose vascular anomaly treated with sirolimus: successful outcome in two patients JO - Pediatr Dermatol VL - 34 UR - https://doi.org/10.1111/pde.13260 DO - 10.1111/pde.13260 ID - Erickson2017 ER - TY - JOUR AU - Fernandez-Pineda, I. AU - Marcilla, D. AU - Downey-Carmona, F. J. AU - Roldan, S. AU - Ortega-Laureano, L. AU - Bernabeu-Wittel, J. PY - 2014 DA - 2014// TI - Lower extremity fibro-adipose vascular anomaly (FAVA): a new case of a newly delineated disorder JO - Ann Vasc Dis VL - 7 UR - https://doi.org/10.3400/avd.cr.14-00049 DO - 10.3400/avd.cr.14-00049 ID - Fernandez-Pineda2014 ER - TY - JOUR AU - Youssefian, L. AU - Vahidnezhad, H. AU - Baghdadi, T. AU - Ghaznavi, A. AU - Li, Q. AU - Tabrizi, M. PY - 2015 DA - 2015// TI - Fibroadipose hyperplasia versus Proteus syndrome: segmental overgrowth with a mosaic mutation in the PIK3CA gene JO - J Invest Dermatol VL - 135 UR - https://doi.org/10.1038/jid.2015.15 DO - 10.1038/jid.2015.15 ID - Youssefian2015 ER - TY - JOUR AU - Lindhurst, M. J. AU - Parker, V. E. AU - Payne, F. PY - 2012 DA - 2012// TI - Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA JO - Nat Genet VL - 44 UR - https://doi.org/10.1038/ng.2332 DO - 10.1038/ng.2332 ID - Lindhurst2012 ER - TY - JOUR AU - Luks, V. L. AU - Kamitaki, N. AU - Vivero, M. P. PY - 2016 DA - 2016// TI - Lymphatic and other vascular malformative/overgrowth disorders are caused by somatic mutations in PIK3CA JO - J Pediatr VL - 166 UR - https://doi.org/10.1016/j.jpeds.2014.12.069 DO - 10.1016/j.jpeds.2014.12.069 ID - Luks2016 ER - TY - JOUR AU - Vanhaesebroeck, B. AU - Stephens, L. AU - Hawkins, P. PY - 2012 DA - 2012// TI - PI3K signalling: the path to discovery and understanding JO - Nat Rev Mol Cell Biol VL - 13 UR - https://doi.org/10.1038/nrm3290 DO - 10.1038/nrm3290 ID - Vanhaesebroeck2012 ER - TY - JOUR AU - Manteuffel, S. R. AU - Dennis, P. B. AU - Pullen, N. AU - Gingras, A. C. AU - Sonenberg, N. AU - Thomas, G. PY - 1997 DA - 1997// TI - The insulin-induced signalling pathway leading to S6 and initiation factor 4Ebinding protein 1 phosphorylation bifurcates at a rapamycin-sensitive pointimmediately upstream of p70s6k JO - Mol Cell Biol VL - 17 UR - https://doi.org/10.1128/MCB.17.9.5426 DO - 10.1128/MCB.17.9.5426 ID - Manteuffel1997 ER - TY - JOUR AU - Whalen, S. G. AU - Gingras, A. C. AU - Amankwa, L. PY - 1996 DA - 1996// TI - Phosphorylation of eIF-4E on serine 209 by protein kinase C is inhibited by the translational repressors, 4E-binding proteins JO - J Biol Chem VL - 271 UR - https://doi.org/10.1074/jbc.271.20.11831 DO - 10.1074/jbc.271.20.11831 ID - Whalen1996 ER - TY - JOUR AU - Dennis, P. B. AU - Pullen, N. AU - Kozma, S. C. AU - Thomas, G. PY - 1996 DA - 1996// TI - The principal rapamycin-sensitive p70 (s6k) phosphorylation sites, T-229 and T-389, are differentially regulated by rapamycin-insensitive kinase kinases JO - Mol Cell Biol VL - 16 UR - https://doi.org/10.1128/MCB.16.11.6242 DO - 10.1128/MCB.16.11.6242 ID - Dennis1996 ER - TY - JOUR AU - Gingras, A. C. AU - Raught, B. AU - Sonenberg, N. PY - 2001 DA - 2001// TI - Regulation of translation initiation by FRAP/mTOR JO - Genes Dev VL - 15 UR - https://doi.org/10.1101/gad.887201 DO - 10.1101/gad.887201 ID - Gingras2001 ER - TY - JOUR AU - Gao, X. AU - Zhang, Y. AU - Arrazola, P. AU - Hino, O. AU - Kobayashi, T. AU - Yeung, R. S. PY - 2002 DA - 2002// TI - Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling JO - Nat Cell Biol VL - 4 UR - https://doi.org/10.1038/ncb847 DO - 10.1038/ncb847 ID - Gao2002 ER - TY - JOUR AU - Adams, D. M. AU - Trenor, C. C. AU - Hammill, A. M. PY - 2016 DA - 2016// TI - Efficacy and safety of Sirolimus in the treatment of complicated vascular anomalies JO - Pediatrics. VL - 137 UR - https://doi.org/10.1542/peds.2015-3257 DO - 10.1542/peds.2015-3257 ID - Adams2016 ER - TY - JOUR AU - Maruani, A. AU - Boccara, O. AU - Bessis, D. PY - 2018 DA - 2018// TI - Treatment of voluminous and complicated superficial slow-flow vascular malformations with sirolimus (PERFORMUS): protocol for a multicenter phase 2 trial with a randomized observational-phase design JO - Trials. VL - 19 UR - https://doi.org/10.1186/s13063-018-2725-1 DO - 10.1186/s13063-018-2725-1 ID - Maruani2018 ER - TY - JOUR AU - No, J. H. AU - Jeon, Y. T. AU - Park, I. A. PY - 2011 DA - 2011// TI - Activation of mTOR signaling pathway associated with adverse prognostic factors of epithelial ovarian cancer JO - Gynecol Oncol VL - 121 UR - https://doi.org/10.1016/j.ygyno.2010.12.364 DO - 10.1016/j.ygyno.2010.12.364 ID - No2011 ER - TY - JOUR AU - Ma, B. L. AU - Shan, M. H. AU - Sun, G. AU - Ren, G. H. AU - Dong, C. AU - Yao, X. PY - 2015 DA - 2015// TI - Immunohistochemical analysis of phosphorylated mammalian target of rapamycin and its downstream signaling components in invasive breast cancer JO - Mol Med Rep VL - 12 UR - https://doi.org/10.3892/mmr.2015.4037 DO - 10.3892/mmr.2015.4037 ID - Ma2015 ER - TY - JOUR AU - Patel, V. AU - Marsh, C. A. AU - Dorsam, R. T. PY - 2011 DA - 2011// TI - Decreased Lymphangiogenesis and lymph node metastasis by mTOR inhibition in head and neck cancer JO - Cancer Res VL - 71 UR - https://doi.org/10.1158/0008-5472.CAN-10-3192 DO - 10.1158/0008-5472.CAN-10-3192 ID - Patel2011 ER - TY - JOUR AU - Hori, Y. AU - Ozeki, M. AU - Hirose, K. PY - 2020 DA - 2020// TI - Analysis of mTOR pathway expression in lymphatic malformation and related diseases JO - Pathol Int VL - 70 UR - https://doi.org/10.1111/pin.12913 DO - 10.1111/pin.12913 ID - Hori2020 ER - TY - JOUR AU - Gutierrez, A. AU - Snyder, E. L. AU - Marino-Enriquez, A. PY - 2011 DA - 2011// TI - Aberrant AKT activation drives well-differentiated liposarcoma JO - Proc Natl Acad Sci U S A VL - 108 UR - https://doi.org/10.1073/pnas.1106127108 DO - 10.1073/pnas.1106127108 ID - Gutierrez2011 ER - TY - JOUR AU - Faried, L. S. AU - Faried, A. AU - Kanuma, T. PY - 2008 DA - 2008// TI - Expression of an activated mammalian target of rapamycin in adenocarcinoma of the cervix: a potential biomarker and molecular target therapy JO - Mol Carcinog VL - 47 UR - https://doi.org/10.1002/mc.20402 DO - 10.1002/mc.20402 ID - Faried2008 ER - TY - JOUR AU - Kurek, K. C. AU - Luks, V. L. AU - Ayturk, U. M. PY - 2012 DA - 2012// TI - Somatic mosaic activating mutations in PIK3CA cause CLOVES syndrome JO - Am J Hum Genet VL - 90 UR - https://doi.org/10.1016/j.ajhg.2012.05.006 DO - 10.1016/j.ajhg.2012.05.006 ID - Kurek2012 ER - TY - JOUR AU - Boscolo, E. AU - Coma, S. AU - Luks, V. L. AU - Greene, A. K. AU - Klagsbrun, M. AU - Warman, M. L. PY - 2015 DA - 2015// TI - AKT hyper-phosphorylation associated with PI3K mutations in lymphatic endothelial cells from a patient with lymphatic malformation JO - Angiogenesis. VL - 18 UR - https://doi.org/10.1007/s10456-014-9453-2 DO - 10.1007/s10456-014-9453-2 ID - Boscolo2015 ER - TY - JOUR AU - Loconte, D. C. AU - Grossi, V. AU - Bozzao, C. PY - 2015 DA - 2015// TI - Molecular and functional characterization of three different postzygotic mutations in PIK3CA-related overgrowth Spectrum (PROS) patients: effects on PI3K/AKT/mTOR signaling and sensitivity to PIK3 inhibitors JO - PLoS One VL - 10 UR - https://doi.org/10.1371/journal.pone.0123092 DO - 10.1371/journal.pone.0123092 ID - Loconte2015 ER - TY - JOUR AU - Kerjaschki, D. PY - 2007 DA - 2007// TI - How to control lymphangiogenesis: a novel role for rapamycin JO - Kidney Int VL - 71 UR - https://doi.org/10.1038/sj.ki.5002184 DO - 10.1038/sj.ki.5002184 ID - Kerjaschki2007 ER -